Clinical news from the XVI International AIDS Conference: The attempt of a summing up.
Topics highlighted at the XVI International AIDS Conference in Toronto included HIV/AIDS vaccine research, entry inhibitors, integrase inhibitors, new NNRTIs and PIs, single-agent therapies, pre-exposure prophylaxis and microbicides. Beside the large scientific part, policy and funding were of great concern. Within this article we are trying to focus on topics with direct clinical relevance. This includes new epidemiological and resistance data, results from current studies investigating established and novel antiretroviral drugs and drug classes as well as new findings in therapy management and strategies.
Jülg
B
B
Dept. of Infectious Diseases, Medical Policlinic, Ludwig Maximilian University Munich, Pettenkoferstr. 8a, 80336, Munich, Germany.
Goebel
F D
FD
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D004359:Drug Therapy, Combination; D006801:Humans
D019380:Anti-HIV Agents